Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2-OH or —CH2—CH2OH, and X is ?O, (H, H) or (H, OH).

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2-OH or —CH2—CH2—OH, and X is ?O, (H, H) or (H, OH).

Abstract: A cell preparation for treating brain tumors used in combination with a prodrug of a drug that kills, or inhibits proliferation of, tumor cells, wherein the cell preparation comprises neural stem cells derived from iPS cells or ES cells having a suicide gene, and the prodrug is a prodrug activated with an enzyme produced by expression of the suicide gene comprised in the neural stem cells is provided to solve the difficulty of obtaining neural stem cells, which is problematic, and to establish new means for treating brain tumors using neural stem cells.

Abstract: A therapeutic agent for amyotrophic lateral sclerosis including a compound represented by Formula (1) [in Formula (1), R1 each independently represents an alkyl group having 1 to 6 carbon atoms or 4-hydroxyphenethyl group, and n represents an integer of 1 to 3], a pharmaceutically acceptable salt thereof, or a solvate thereof, as an effective ingredient.

Abstract: A method for producing a tau-related disease model is provided. The method includes three-dimensionally culturing pluripotent stem cells having a mutation in a Microtubule Associated. Protein Tau (MAPT) gene to form a nerve organoid, and dissociating the nerve organoid into single cells and performing two-dimensional adherent culture to obtain neurons, in which the neurons are a tau-related disease model.

Abstract: This invention relates to methods for treating hearing loss associated with loss of cochlear hair cells, e.g., caused by noise exposure, using certain gamma secretase inhibitors, in post-neonatal animals, e.g., adolescents and adults.

Abstract: To produce and/or maintain naïve pluripotent stem cells capable of highly expressing genes important for maintaining an undifferentiated state, which could not be achieved by known methods for producing pluripotent stem cells. The present invention can produce naïve pluripotent stem cells capable of maintaining an undifferentiated state by introducing and allowing transient expression of six genes (Oct3/4, Klf4, c-Myc, Sox2, Nanog, and Klf2) among the so-called initializing factors, and further performing culturing in a medium containing LIF, an MEK inhibitor, a GSK3 inhibitor, a cAMP production promoter, a TGF-? inhibitor and a PKC inhibitor. Thus, the problem of the present invention can be solved.

Abstract: Provided is an agent for accelerating maturation or aging of cells. An agent for accelerating maturation or aging of cells, comprising KU-60019 as an active ingredient.

Abstract: A culture medium for inducing a pluripotent stem cell into a differentiation-promoted pluripotent stem cell, the medium including a Glycogen synthase kinase 3? (GSK3?) inhibitor, a Bone morphogenic protein (BMP) signaling inhibitor, and a Transforming growth factor (TGF)-? inhibitor as active ingredients.

Abstract: To produce and/or maintain naïve pluripotent stem cells capable of highly expressing genes important for maintaining an undifferentiated state, which could not be achieved by known methods for producing pluripotent stem cells. The present invention can produce naïve pluripotent stem cells capable of maintaining an undifferentiated state by introducing and allowing transient expression of six genes (Oct3/4, Klf4, c-Myc, Sox2, Nanog, and Klf2) among the so-called initializing factors, and further performing culturing in a medium containing LIF, an MEK inhibitor, a GSK3 inhibitor, a cAMP production promoter, a TGF-? inhibitor and a PKC inhibitor. Thus, the problem of the present invention can be solved.

Abstract: A pump housing of the carbon dioxide-containing gas recovery apparatus is formed with a first chamber and a second chamber partitioned by a partition wall. The first and second chambers and communicate with each other through a third chamber. The first chamber communicates with a water supply opening and a carbon dioxide-containing gas inlet. When blown against water filling the first chamber, a carbon dioxide-containing gas is dissolved in the water, and the carbon dioxide-containing gas remaining undissolved exists as bubbles in the water. When a pair of six-blade rotors oppositely disposed on two axes and in the third chamber compress the bubbles to be refined into different bubbles, the carbon dioxide-containing gas can further be dissolved in the water by a compression action. An aqueous solution of carbon dioxide-containing gas is discharged from a water outlet communicating with the second chamber.

Abstract: A method is provided for uniformly differentiating a pluripotent stem cell into a neural stem cell, with elimination of variation among cell strains or clones of the pluripotent stem cell and without formation of an embryoid body, regardless of the origin of the pluripotent stem cell

Abstract: This invention relates to methods for treating hearing loss associated with loss of cochlear hair cells, e.g., caused by noise exposure, using certain gamma secretase inhibitors, in post-neonatal animals, e.g., adolescents and adults.

Abstract: A method for differentiating a human differentiated cell-derived pluripotent stem cell into a neural stem cell is provided, which includes the steps of: making an embryoid body from the human differentiated cell-derived pluripotent stem cell; and culturing the embryoid body in a medium containing LIF to differentiate into a neural stem cell, so that, when the neural stem cell is allowed to differentiate in vitro after multiple subculturing of the neural stem cell, it differentiate mainly into neurons but substantially not into glial cells.

Abstract: [Problem] Providing a carbon dioxide-containing gas recovery-apparatus which is low in cost and can improve a carbon dioxide-containing gas recovery efficiency. [Overcoming Means] A pump housing 11 of the carbon dioxide-containing gas recovery apparatus 10 is formed with a first chamber 23 and a second chamber 26 partitioned by a partition wall 20a. The first and second chambers 23 and 26 communicate with each other through a third chamber 20. The first chamber 23 communicates with a water supply opening and a carbon dioxide-containing gas inlet. When blown against water filling the first chamber, a carbon dioxide-containing gas is dissolved in the water, and the carbon dioxide-containing gas remaining undissolved exists as bubbles A in the water. When a pair of six-blade rotors 40 oppositely disposed on two axes 41a and 41b in the third chamber 20 compress the bubbles A to be refined into bubbles B, the carbon dioxide-containing gas can further be dissolved in the water by a compression action.

Abstract: To produce and/or maintain naïve pluripotent stem cells capable of highly expressing genes important for maintaining an undifferentiated state, which could not be achieved by known methods for producing pluripotent stem cells. The present invention can produce naïve pluripotent stem cells capable of maintaining an undifferentiated state by introducing and allowing transient expression of six genes (Oct3/4, Klf4, c-Myc, Sox2, Nanog, and Klf2) among the so-called initializing factors, and further performing culturing in a medium containing LIF, an MEK inhibitor, a GSK3 inhibitor, a cAMP production promoter, a TGF-? inhibitor and a PKC inhibitor. Thus, the problem of the present invention can be solved.

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2-OH or —CH2—CH2OH, and X is ?O, (H, H) or (H, OH).

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2—OH or —CH2—CH2—OH, and X is ?O, (H, H) or (H, OH).

Abstract: The present invention aims to obtain a method for quality evaluation of human mesenchymal stem cells, a method for isolation, selection and culture of human mesenchymal stem cells, a cell population of rapidly proliferating human mesenchymal stem cells, as well as monoclonal antibodies that specifically recognize rapidly proliferating human mesenchymal stem cells. From a cell population containing human mesenchymal stem cells, rapidly proliferating human mesenchymal stem cells are isolated, selected and cultured. The abundance ratio of cells expressing Ror2 or Fzd5 in the cell population thus isolated, selected and cultured is quantified to determine whether or not each cell population is acceptable.

Abstract: In order to provide a method for producing neural stem cells easily and quickly by inducing differentiation of somatic cells directly into neurospheres, dedifferentiation factors are introduced into somatic cells, which are then cultured in suspension in the presence of growth factors to produce the neurospheres, thereby allowing the neural stem cells to be produced quickly without establishing iPS cells.